| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8372968 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8895721 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US9567582 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8552171 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(3 years ago) | |
| US8895718 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8362231 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(1 year, 28 days from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193753 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(3 years ago) | |
| US8778902 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(5 months ago) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(5 months ago) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(3 years from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(6 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(6 years from now) | |
Onpattro is owned by Alnylam Pharms Inc.
Onpattro contains Patisiran Sodium.
Onpattro has a total of 24 drug patents out of which 10 drug patents have expired.
Expired drug patents of Onpattro are:
- US9193753
- US8778902
- US9943539
- US9943538
- US8372968
- US8895721
- US9567582
- US8552171
- US8895718
- US8362231
Onpattro was authorised for market use on 10 August, 2018.
Onpattro is available in solution;intravenous dosage forms.
Onpattro can be used as treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Drug patent challenges can be filed against Onpattro from 10 August, 2022.
The generics of Onpattro are possible to be released after 27 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
ONPATTRO family patents
